Life-years lost by COVID-19 patients in public hospitals of Marseille (APHM-South-Eastern France): a limited death toll: a retrospective analysis

Sylvie Arlotto,1,2 Alice Garès,1,2 Audrey Giraud-Gatineau,3,4 Jean Cristophe Lagier,1,5 Marie-Thérèse Jimeno,6 Patrick Peretti-Watel,3,7 Matthieu Million,1,5 Philippe Parola,3,8 Philippe Brouqui,6,8 Didier Raoult,1,5 Stephanie Gentile9,10

ABSTRACT

Objective Between 1 March and 15 June, France experienced the first wave of the COVID-19 pandemic, during which 29,549 deaths occurred among COVID-19 patients, 17,250 of whom died in hospital. Our hypothesis is that crude mortality rates are not sufficient to assess the impact of the epidemic on public health. The objective of this paper is to estimate the potential years of life lost (YLL) of patients who died from COVID-19.

Method We realised a retrospective analysis of the exhaustive sample of COVID-19 PCR-positive patients who died in public hospitals of Marseille during this first wave. Data on demographic characteristics, comorbidities and care pathways were collected from medical records. The Charlson Comorbidity Index (CCI) was used to assess what would have been the probability of dying within 1 year of these patients in the absence of COVID-19 and to estimate total YLL.

Results Among the 1,631 patients who were hospitalised for COVID-19, 178 patients died, at an average age of 80 years. According to CCI, 88.8% of the deceased patients had an 85% probability of dying within 1 year before COVID-19. Among the 11.2% who had a lower CCI probability, 18 out of 20 had at least one additional comorbidity known to be a major risk factor of mortality in COVID-19 disease. Cumulative total number of YLL was estimated to be 541 in this deceased population, that is, an average of 3 YLL.

Conclusion Although our results should be interpreted with caution, this analysis confirms that mortality due to COVID-19 translates into a limited number of YLL due to both old age and preexisting comorbidities in the most vulnerable patients. This fact should be better considered in public health management of the pandemic both for risk communication and design of the most appropriate protective measures.

INTRODUCTION

In France, as in most other European countries, the COVID-19 pandemic has gone through two phases: while the first cases of SARS-CoV-2 were recorded on 24 January 2020 the ‘first epidemic wave’ officially took place between 1 March 2020 and 15 June 2020; a ‘second wave’ started in September and then declined, although at a quite slow pace, at the end of October.1

Detailed national statistics are available about deaths attributable to COVID-19 during the first wave2 and it has been argued that public health measures implemented by national authorities have been effective in reducing the death toll due to SARS-CoV-2.3–5 Indeed, during this first wave, the French government, implemented a national lockdown during 55 days lasting from 17 March 2020 to 11 May 2020, with a very significant impact both on the use of care6 and economic activity.7 8 COVID-19 had a major indirect impact on people who did not become infected. For example, people with emergency health needs have sometimes struggled to receive timely acute care, and those with chronic health conditions have faced disruptions to routine care. In addition, the
pandemic and the subsequent economic crisis have led to a growing burden of mental ill health, with emerging evidence of higher rates of stress, anxiety and depression; compounded by disruptions to healthcare for those with pre-existing mental health conditions.\textsuperscript{9} 10

However, because COVID-19 frequently causes death in the old and frail, and those with underlying chronic conditions,\textsuperscript{11} 12 the absolute death toll or excess mortality rates do not provide enough information to measure the actual impact of the epidemic. A more relevant measure of the relative public health impact of such an epidemic is the measurement of potential years of life lost (YLL).\textsuperscript{13} Indeed, considering the age of death rather than the simple event of death allows a different weight to be assigned to deaths at different times of life. The presumption underlying YLL is that a more ‘premature’ death (ie, at a younger age) will result in a greater loss of life and should be given a higher value from society’s standpoint. YLL is often used in comparing the health system performance of countries in addressing major killer diseases and informs health policy. Moreover, several studies suggest that YLL should be corrected for comorbidities of the deceased.\textsuperscript{14}

The objective of this paper is to estimate the number of potential YLL for patients who died of COVID-19 in the Assistance Publique-Hôpitaux de Marseille (AP-HM) and to estimate the impact of comorbidities on this number, from a complete analysis of the sociodemographic and medical profiles of the deceased patients.

**Design and patient selection**

Our study is based on data from the AP-HM, which is the third largest university hospital centre in France. AP-HM is made up of four public hospitals and has 3400 beds, including 162 intensive care beds. In addition, it includes a facility especially devoted to management of infectious diseases and related epidemic situations, the University Hospital Institute of Mediterranean Infections (IHU) with 75 inpatient beds, a day hospital, an outpatient department with 14 consultation rooms and a travel clinic.

We performed a retrospective analysis of PCR-positive patients hospitalised and deceased at the ‘AP-HM’ from 1 March 2020 to 15 June 2020.

**Patient and public involvement**

No patient involved.

**Data collection**

During this period, data on all inpatient deaths (COVID-19 and non-COVID-19) and the number of hospitalisations of patients with COVID-19 were extracted from the hospital’s information system, which is linked to the French National Uniform Hospital Discharge Database.\textsuperscript{15} All data collected were anonymised

For patients who were registered as having died from COVID-19, we collected data from their patients’ medical records but in addition, these files were reviewed by an expert group of physicians to ultimately validate data on the patient’s demographics and lifestyle, pre-existing comorbidities, care pathway and cause of death. For each patient, we checked that death was effectively due to COVID-19 and verified that it could not be attributed to another disease (eg, cancer). In addition, comorbidities diagnosed prior to hospital admission were collected based on anamnestic data.

In total, the following data were collected:

**Sociodemographic data**

Gender, age, date of death.

**Data concerning in-hospital care pathway**

The admission type (directly from home, from the emergency departments or transferred from another hospital), their transfer to the intensive care unit, the length of hospital stay, and the number of patients in limitation and discontinuation of active therapies.

**Lifestyle**

Where the patient lived (institution or at home), and loss of autonomy, that is, when it was specified in the medical file that the patient needed help for the activities of daily living and if the patient was bedridden or not

**Patients’ comorbidities**

We used the Charlson Comorbidity Index (CCI) to assess what would have been the probability of death within 1 year of these patients in the absence of COVID-19.\textsuperscript{16} This index is designed to predict 1-year mortality on the basis of a weighted composite score for the following categories: cardiovascular, endocrine (only diabetes), pulmonary, neurologic, renal, hepatic, gastrointestinal and neoplastic diseases. It considers 19 comorbidities. Comorbidities are weighted from 1 to 6 for mortality risk and disease severity. The final score is obtained by summation of the weighted comorbidity scores adjusted on the patient’s age (1 point for each decade from the age of 41 years). The higher the score, the higher the likelihood of mortality is within a 1-year period according to the following algorithm: Score=0 → estimated 1-year mortality=12%; score=1–2 → estimated 1-year mortality=26%; score=3–4 → estimated 1-year mortality=52%; score ≥5 → estimated 1-year mortality=85% or more.

In addition, we also collected comorbidities that are not included in the CCI but are well known for being risk factors of aggravated morbidity and mortality in COVID-19 patients (obesity, hypertension, sleep apnoea, asthma, hypothyroidism, dyslipidaemia, psychiatric disease and neurological pathology—excluding dementia).

**Statistical analysis**

To estimate the number of potential YLL, we first used the life expectancy table of the French Institute for Demographic,\textsuperscript{17} which estimates, according to gender, the YLL for an individual at a given age. This table goes up to the age of 90 years; after this age, the number of residual years of life is estimated to be zero. From the table, we...
reported to our database the number of years of residual life for each deceased patient.

Then to adjust the number of potential YLL we used the following formula for each patient

$\text{YYL}_c = \sum_{i=1}^{n} \left(1 - CCI_i \right) \times \text{YYL}_i$

$\text{YYL}_c=$Sum of the number of potential YLL adjusted to age, sex and CCI for a given age stratum
$n=$number of patients in the age stratum
$CCI_i=$probability of dying in the year according the CCI for person i
$\text{YYL}_i=$number of potential YLL for person i adjusted on sex and age according to The French Institute for Demographic Studies

The cumulative number of potential YLL (with and without CCI adjustment) was tabulated by age group: 0–40 years of age; 41–50 years of age; 51–60 years of age; 61–70 years of age; 71–80 years of age; 81–90 years of age; 90 years of age and over.

The dichotomous variables were described as whole integers and percentages, and the continuous variables as mean and standard deviation (or median and IQR in those with no criteria of normal distribution). The distribution of all variables was analysed with the Kolmorogov-Smirnov test. The associations between qualitative variables were measured by the χ² square test or the Fischer’s exact test for small numbers. A student’s t-test or analysis of variance was performed for the quantitative variable. All statistical analyses were performed using SPSS (V.20.0, IBM). P values were two sided, and the significance level was 0.05.

RESULTS

Between 1 March 2020 and 15 June 2020, a total of 1631 patients were hospitalised for COVID-19 at APHM, including 702 at the IHU and 929 in other departments. Among them 178 ultimately died with death being attributable to COVID-19 with certainty, that is, a mortality rate of 10.9%.

At the Marseille University Hospitals, in the 3 years before 2020, there was an average of 246 deaths per month. Table 1 presents descriptive statistics about demographic and clinical characteristics of COVID-19-deceased patients as well as comparison between the greatest majority (n=158) who had an a priori 85% probability or more of dying within 1 year according to CCI calculation versus those who did not (n=20). Mean age at death was 80 years (25th percentile 72.8, median 82, 75th percentile 89) and nearly two-thirds of deceased patients were men. Also, nearly two-thirds of patients were frail and 18% were already bedridden before their COVID-19 hospitalisation. More than two-thirds (70.8%) of patients directly entered the hospital through the emergency departments. The most common care pathway was direct admission to the emergency department, followed by a conventional hospitalisation (54.5%). One-quarter of patients (25.8%) were transferred to intensive care during their hospitalisation, and more than half of them (56.5%) were admitted in ICU within the first 24 hours after their admission.

The most common comorbidities included in the CCI were dementia (29%), uncomplicated diabetes (27%) and chronic pulmonary disease (17%). Among comorbidities not included in the CCI, hypertension was the most common (68.4%).

All deaths were clearly attributable to COVID-19 disease. All died because of acute respiratory syndrome, except three patients who died as a result of arterial thrombotic disease: stroke, myocardial infarction and mesenteric ischaemia, pathologies that we have linked to coagulation disorders induced by SARS-CoV-2.

Estimation of probability of mortality at one year

According to CCI, 88.8% of patients had an 85% probability of dying within 1 year, 10.1%, a 52% probability (n=18), one patient 26% and one 12%.

Analysis by age group shows that 34 patients were under 71 years. Of these, 19 had an 85% probability of dying within 1 year according to CCI. The profile of these 34 patients is presented in online supplemental table 1. They all had withdrawal comorbidities except for three patients for whom no comorbidity was found.

Only, two deceased patients who died were less than 51 years. They already had poor prognosis before COVID-19: one was an institutionalised bedridden patient with multiple severe comorbidities, and the other had a severe autoimmune disease with a history of myocarditis related to a viral infection (influenza).

Ten patients who died were between 50 and 60 years old. Among them 5 patients had 85% probability of dying within 1 year, one was bedridden with six comorbidities, three had metastasised cancer, and one had seven comorbidities, including chronic respiratory failure requiring home oxygen therapy. Four patients had 52% probability of dying within a year according to CCI score, one was already institutionalised for severe dementia and the other three patients had cardiac and pulmonary significant comorbidities and had to be transferred to ICU during the first 24 hours after admission due to a severe clinical condition. Only one patient in this age group had no comorbidities and had 26% probability of death according to CCI.

Twenty-two patients who died were between 50 and 60 years old. Among them, 14 had 85% probability of dying within 1 year according to CCI, 8 already presented a loss of autonomy, including 3 bedridden patients. They all had numerous comorbidities such as dementia or the triad of diabetes, obesity and hypertension. The three patients who had less than three comorbidities suffered from cancer, including two metastatic ones. Eight patients had 52% probability of dying within a year according to CCI score, one was already institutionalised with serious pathologies and five patients had at least two of three major risk factors for COVID-19 mortality: obesity, diabetes and/or cardiovascular pathologies.

Arlotto S, et al. BMJ Open 2021;11:e049475. doi:10.1136/bmjopen-2021-049475

Open access
### Table 1  Demographic, clinical characteristics and Charlson Comorbidity Index of COVID-19 +deceased patients in Marseille (South Eastern France (public hospitals—March/June 2020 (n=178)

| Probability of dying within 1 year | Total | >85% | <85% | P value |
|------------------------------------|-------|------|------|---------|
| No of patients                     | 178   | 158  | 20   | 0.365   |
| Men % (n)                          | 60.7 (108) | 59.5 (94) | 70 (14) | <0.001 |
| Age group % (n)                    |       |      |      |         |
| 0–40                               | 0.6 (1) | 0 (0) | 5 (1) |         |
| 40–50                              | 0.6 (1) | 0 (0) | 5 (1) |         |
| 51–60                              | 5.6 (10) | 3.2 (5) | 25 (5) | <0.001 |
| 61–70                              | 12.4 (22) | 8.9 (14) | 40 (8) |         |
| 71–80                              | 27.5 (49) | 27.8 (44) | 25 (5) |         |
| 81–90                              | 37.1 (66) | 42 (66) | 0 (0) |         |
| >90                                | 16.6 (29) | 18.5 (29) | 0 (0) |         |
| Quality of life style data         |       |      |      |         |
| Living in institutionalisation % (n) | 24.7 (44) | 26.6 (42) | 10 (2) | 0.106   |
| Bedridden and living in institutionalisation % (n) | 11.2 (20) | 12 (19) | 5 (1) |         |
| Loss of autonomy and living at home % (n) | 21.3 (38) | 24.1 (38) | 0 (0) | <0.001 |
| Bedridden and living at home % (n) | 6.7 (12) | 7.6 (12) | 0 (0) | 0.210   |
| Charlson Comorbidity Index         |       |      |      |         |
| Myocardial infarct % (n)           | 17.4 (31) | 19.0 (30) | 5 (1) | 0.207   |
| Congestive heart failure % (n)     | 14.6 (26) | 16.5 (26) | 0 (0) | 0.048   |
| Peripheral vascular disease % (n)  | 12.9 (23) | 22 (13.9) | 5 (1) | 0.478   |
| Cerebrovascular disease % (n)      | 11.8 (21) | 13.3 (21) | 0 (0) | 0.136   |
| Dementia % (n)                     | 28.7 (51) | 31 (49) | 10 (2) | 0.050   |
| Chronic pulmonary disease % (n)    | 16.9 (30) | 17.7 (28) | 10 (2) | 0.534   |
| Connective tissue disease % (n)    | 1.7 (3) | 1.9 (3) | 0 (0) | 1.000   |
| Ulcer disease % (n)                | 5.1 (9) | 5.7 (9) | 0 (0) | 0.600   |
| Mild liver disease % (n)           | 1.7 (3) | 1.9 (3) | 0 (0) | 1.000   |
| Diabetes % (n)                     | 27 (48) | 27.2 (43) | 25 (5) | 0.833   |
| Hemiplegia % (n)                   | 1.7 (3) | 1.9 (3) | 0 (0) | 1.000   |
| Moderate or severe renal disease % (n) | 12.4 (22) | 13.9 (22) | 0 (0) | 0.075   |
| Diabetes with end organ damage % (n) | 2.2 (4) | 2.5 (4) | 0 (0) | 1.000   |
| Active tumour % (n)                | 10.1 (18) | 11.4 (18) | 0 (0) | 0.111   |
| Leukaemia % (n)                    | 0 (0) | 0 (0) | 0 (0) |         |
| Lymphoma % (n)                     | 3.4 (6) | 3.8 (6) | 0 (0) | 1.000   |
| Moderate or severe liver disease % (n) | 1.7 (3) | 1.9 (3) | 0 (0) | 1.000   |
| Metastatic solid tumour % (n)      | 5.6 (10) | 6.3 (10) | 0 (0) | 0.606   |
| AIDS % (n)                         | 0 (0) | 0 (0) | 0 (0) |         |
| Other comorbidities                |       |      |      |         |
| Obesity % (n)                      | 11.8 (21) | 8.9 (14) | 35 (7) | 0.003   |
| Asthma % (n)                       | 5.6 (10) | 5.1 (8) | 10 (2) | 0.312   |
| Hypertension % (n)                 | 68.4 (117) | 68.4 (108) | 45 (9) | 0.038   |
| Sleep apnoea % (n)                 | 7.3 (13) | 6.4 (10) | 15 (3) | 0.166   |
| Dyslipidaemia % (n)                | 14.6 (26) | 15.8 (25) | 5 (1) | 0.316   |
| Hypothyroidism % (n)               | 8.4 (15) | 8.9 (14) | 5 (1) | 1.00    |
| Psychiatric disease                | 15.2 (27) | 15.2 (24) | 15 (3) | 1.000   |

Continued
Finally, two patients without significant comorbidities had been directly hospitalised through the emergency departments and were transferred to intensive care, one of them within the first 24 hours.

If comorbidities were not considered, the estimated total number of YLL in the deceased population would have been 1776 years, that is, an average of 10 years per patient. Considering the CCI to adjust for pre-existing comorbidities leads to a reduced, more accurate estimation of 541 YLL, that is, an average of 2.5 potential YLL (table 2).

**DISCUSSION**

During the period studied, the first wave of the COVID-19 pandemic in France, a total of 17,250 inpatients died from COVID-19 in France, of which 870 in the Marseille region. Our analysis of COVID-19-related deaths in public hospitals of Marseille, the main city in this geographical area, represents 20.4% of the total death toll from COVID-19 in this region.18

Surprisingly, we saw a decrease in the total number of deaths in the Marseille public hospitals from all causes during this first epidemic phase, with excess mortality due to COVID-19 being observed only during the 4 weeks of the month of April. In line, the national statistics showed that 80% of COVID-19-related deaths occurred in April.18 This may be explained by the deprogramming of care for non-COVID-19 and non-urgent patients and the generalised lockdown that forced people to stay home away from emergency care.6

Three-quarters of COVID-19-deceased patients included in our analysis were admitted to hospital through emergency departments, and of the patients admitted to intensive care, more than half were transferred during the first 24 hours after hospitalisation. These results showing that many patients who ultimately died were admitted in hospitals in an already highly critical condition suggest that medical care pathways prior to hospitalisation had not been optimal. They raise concerns about the appropriateness of the French national recommendations in place during the first lockdown, which encouraged COVID-19 patients to stay isolated at home with no medical follow-up and to wait for clinical symptoms of a worsening condition, mainly based on the appearance of dyspnoea, before calling medical emergency services (Centre SAMU 15).19 Such recommendations may have led to delays in medical consultations for a significant proportion of patients requiring emergency care. Numerous publications have subsequently shown that dyspnoea is not an essential criterion of initial severity for COVID-19-related disease.20 Indeed, in Marseille hospitals, about one third of COVID-19 patients feeling well and without dyspnoea had hypoxaemia (happy or silent hypoxaemia) at time of first admission, which is strongly associated with a poor prognosis.21–22

In our analysis, 88.8% of COVID-19-deceased patients had an 85% probability of dying within 1 year, according to the CCI. Among the various methods used to predict hospital mortality by weighting comorbidities, CCI has been widely applied since many studies demonstrated

### Table 2: Potential years of life lost (YLL) by COVID-19-deceased patients in Marseille hospitals (March–June 2020)

| Age | No of patients | Charlson probability of dying within a year | Probability of dying within 1 year | YLLs using average life expectancy for age & gender | YLL adjusted by Charlson Comorbidity Index |
|-----|----------------|-------------------------------------------|----------------------------------|-------------------------------------------------|-------------------------------------------|
|     |                | 12% | 26% | 52% | 85% |                           |                               |                                              |
| 0–40 | 1              | 1   | 1   |     |     | 57.7                      | 50.8                            |
| 40–50 | 1              | 1   |     | 1   |     | 33                         | 15.8                            |
| 51–60 | 10             | 1   | 1   | 4   | 5   | 264.5                      | 85.2                            |
| 61–70 | 22             | 8   |     | 14  |     | 437.7                      | 117.7                           |
| 71–80 | 49             |     | 5   | 44  |     | 583.3                      | 105.5                           |
| 81–90 | 66             |     |     |     | 66  | 399.1                      | 59.8                            |
| >90   | 29             | 29  |     |     |     | 0                          | 0                               |
| Total | 178            | 1   | 1   | 18  | 158 | 1775.2                     | 434.8                           |
that it is a valid prognostic indicator for mortality.\textsuperscript{23–25} Although the original publication on the Charlson index was in the 1980s, this score, which was updated in the 1990s, remains the most widely used score for predicting hospital mortality. The survival curve has not been updated, however, and the probability of hospital death may be overestimated. Nevertheless, this index has been validated for its ability to predict mortality in various disease subgroups, including cancer, renal disease, stroke, intensive care and liver disease.\textsuperscript{16,\textsuperscript{26–29}} Only 20 of the deceased patients had a lower probability of death within 1 year (<85%) according to CCI but nearly all of them (18 out of 20) exhibited at least two comorbidities (obesity, hypertension, diabetes, etc) that are not included in the CCI but are well-known for being major risk factors of severity and mortality in the case of COVID-19 infection.

Our paper shows that number of YYL is much lower when adjusting for patient comorbidities; it decreased from an average to 2.4 years. Our analysis has tended to overestimate the total number of YYL since the Charlson score does not include some comorbidities that are major risk factors in the context of COVID-19. It is not possible to adjust the number of YYL for patients who had important conditions that are not accounted for in the Charlson score, such as disabling genetic diseases, advanced Parkinson’s disease, or morbid obesity. In addition, we used the table of the French Institute for Demographic, which gives residual years of life up to age 90, whereas most of the tables used in other studies only go up to age 75/80. Knowing that 57% of our population was older than 80 years, if we had taken this age as the threshold beyond which the number of residual years is considered zero, we could have reduced the 339.8 YYL without adjustment and the 117 YYL after adjustment for these patients to 0. For these reasons, although we are aware that the probability of dying within 1 year for hospitalised patients according to the Charlson score is certainly overestimated due to medical progress since its validation date, we do not believe that we have underestimated the number of YYL. Finally, in our population, half of the youngest patients, that is, the 10 under 60 years of age, had a highly comorbid profile (eg, 3/5 had metastasised cancer).

Of the 178 deceased patients, only three died without a diagnosed comorbidity. In an Italian study like ours, only 4% of the patients had no comorbidities (29). Overall, as in the Italian study, we found a quarter (27%) of all our deceased patients had at least 2 of the 3 comorbidities (diabetes, obesity or hypertension) that are the main risk factors for COVID-19 disease.\textsuperscript{24} The main result of our study is that the largest share of COVID-19 mortality occurs among individuals who already had an ex-ante high probability of death within 1 year due to old age and/or pre-existing morbidity. This finding is in line with all previous studies demonstrating that presence of comorbidities is associated with a higher risk of mortality and negative outcomes in COVID-19 patients with pre-existing diseases.\textsuperscript{25,\textsuperscript{30–31}}  

Some limitations must be considered before generalising our findings on the COVID-19 patients followed in the main public hospitals of Marseille during the first wave of the pandemic. First, our analysis focused only on patients dying in hospital and did not include deaths at home or in institutions for managed care of the elderly. It should, however, be noted that on average individuals living in institutions caring for the elderly are 85 years old or more.\textsuperscript{32} YYL due to COVID-19 is likely to have been limited in this population, although reduction of care and social activities, and disruption of family visits that resulted from the lockdown, may have accelerated death of these individuals, and has certainly decreased their quality of life and well-being. The exact causes of death at home during the study period are not yet available, but in any case attributing these deaths to COVID-19 disease will not be easy, as it is now established that during the national first lockdown in France, access to care was significantly reduced for non-COVID-19 patients especially for cardiovascular pathologies, vascular accidents and cancer surgery.\textsuperscript{33–34} However, it is also possible that the social and political measures put in place during the first lockdown reduced the number of deaths due to COVID-19. Second, although the age and gender distribution of patients who died in our sample is similar to that observed at the national level (60% men among the deceased at the national level vs 60% for our hospital, 50% over 80 years of age among the deceased at the level of the national statistics vs our 53.7%) and the time profile of mortality due to COVID-19 is also similar between the public hospitals in Marseille and the national statistics (17), we cannot claim that our results are fully representative of the overall situation in France. Indeed, mortality due to COVID-19 among Marseille hospitalised patients has been significantly lower (11%) than the national (19%) and even regional (14.5%) mortality rates. In Marseille, the presence of the IHU has enabled the early implementation of standardised mass screening and treatment protocols, which may have significantly contributed to quality and safety of care.\textsuperscript{38}

Despite these limitations, our results could be useful to inform public health officials dealing with the COVID-19 pandemic in France and elsewhere. The first-dimension deals with risk communication in the context of an infectious disease pandemic. The management of the COVID-19 epidemic led to an unprecedented situation, in which mortality was highlighted almost constantly, with daily updates of death statistics in social media and news. The wearing of face masks, the use of antibacterial sprays and wipes, as well as social distancing and public health campaigns were also visible and may have been interpreted by some sectors of the population as ubiquitous indicators of death.\textsuperscript{35} It is now well established that daily reporting of the number of deaths, combined with widespread lockdown, has been very prejudicial to the mental health of the general population, in France as in other countries.\textsuperscript{36,37} The absolute number of deaths is an imperfect measure of mortality and is not a good representation...
of the severity of the epidemic, as it does not provide insight into the age distribution of deaths or how risk levels vary by age, and consequently does offer enough information as to how many years of life were lost due to the disease. Our study suggests that the number of deaths should not be communicated to the population without contextualising it, that is, without comparing it to the previous years, and without describing the patient profile (at least age). The crude mortality finding is inconclusive about the overall impact on life expectancy and has been shown to be a poor indicator in the general population. The YLL approach, taking into account comorbidities, gives a more detailed view of the consequences of the epidemic.

Author affiliations
1 Assistance Publique - Hôpitaux de Marseille, Marseille, France
2 Aix-Marseille University, Marseille, France
3 VITROME, IRD, Marseille, France
4 Centre d’Épidémiologie et de Santé Publique des Armées (CESPA), Marseille, France
5 MEPHI, IRD, Marseille, France
6 Service d’Information Médicale Public health Department La Timone Hospital, Marseille, France
7 Research department, Southeastern Health Regional Observatory, Marseille, France
8 Centre d’Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France
9 Service d’Evaluation Médicale, Assistance Publique Hopitaux de Marseille, Marseille, France
10 School of Medicine - La Timone Medical Campus, Aix-Marseille Université, Marseille, France

Contributors SG, SA and DR conceived the research and participated in the study design. SA, SG, AG, AG-G and M-TJ assisted in collecting the data. SA, AG and SG analysed the data. SG and SA drafted the manuscript. SA, AG, AG-G, JCL, M-TJ, PP-W, MM, PP, PB, DR and SG read and approved the final manuscript. SG is guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The data presented were collected retrospectively in an anonymous way from the patient’s medical records in accordance with the European Regulation no 2016/679 General Data Protection Regulation (GDPR) and registered in the hospital’s GDPR registry no 2019-74.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Philippe Brouqui http://orcid.org/0000-0002-6125-2805

REFERENCES
1 Santé Publique France. COVID-19: point épidémiologique du 3 décembre [online]. Santé Publique France, 2020. /maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-mardi-3-decembre-2020-
2 Fouillet A, Pontias L, Caseroir-Schönnemann C. Excess all-cause mortality during the first wave of the COVID-19 epidemic in France, March to May 2020. Eurosurveillance 2020;25.
3 Di Domenico L, Pullano G, Sabatini CE, et al. Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. BMC Med 2020;18:240.
4 De Figueiredo AM, Codina AD, Cristina D. Impact of lockdown on COVID-19 incidence and mortality in China: an interrupted time series study.
5 Siqueira CAD, Freitas YNL, Cancela MDeC, et al. The effect of lockdown on the outcomes of COVID-19 in Spain: an ecological study. PLoS One 2020;15:e0236779.
6 Pullano G, Valdano E, Scarpa N, et al. Evaluating the effect of demographic factors, socioeconomic factors, and risk aversion on mortality during the COVID-19 epidemic in France under lockdown: a population-based study. Lancet Digit Health 2020;2:e638–49.
7 Chen S, Igan D, Piirer N, et al. Tracking the economic impact of COVID-19 and mitigation policies in Europe and the United States. IMF-WP 2020:20.
8 Malliet P, Reynès F, Landa G, et al. Assessing short-term and long-term economic and environmental effects of the COVID-19 crisis in France. Environ Resource Econ 2020;76:867–83.
9 Beck F, Léger D, Flessard L, et al. Covid-19 health crisis and lockdown associated with high level of sleep complaints and hypnic uptake at the population level. J Sleep Res 2021;30:e13119.
10 OECD/European Union. How resilient have European health systems been to the COVID-19 crisis? In: Health at a Glance: Europe 2020: State of Health in the EU Cycle [online]. Paris, 2020.
11 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
12 Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395:1041–54.
13 Maximova K, Rozen S, Springett J, et al. The use of potential years of life lost for monitoring premature mortality from chronic diseases: Canadian perspectives. Can J Public Health 2016;107:e202–4.
14 Cassini A, Högborg LD, Plouchouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019;19:56–66.
15 Boudemaghe T, Belhadj I. Data resource profile: the French national uniform hospital discharge data set database (PMSI). Int J Epidemiol 2017;46:392.
16 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic combinatory in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
17 INED. Tables de mortalité par sexe, âge et niveau de vie – Tables de mortalité par sexe, âge et niveau de vie, France. Insee Internet [online]. Available: https://www.insee.fr/fr/statistiques/3311422?sommaire=3311425&q=table+mortalite+par+sexe+niveau+de+vie
18 Courtejoie N, Dubost C-L. Parcours hospitalier des patients atteints de la Covid-19 lors de la première vague de l’épidémie. DREES 2020:37–39.
19 Ministère des Solidarités et de la Santé. Que faire si la maladie s’aggrave? [online]. Available: https://solidarites-sante.gouv.fr/utty
20 Shenoy N, Luchtel R, Gulani P, et al. Risk and outcome of COVID-19 among critically ill hospitalised patients during the first wave of the COVID-19 pandemic in India: an observational study. Int J Infect Dis 2020;22:1–5.
21 Brouqui P, Amrance S, Million M, et al. Asymmetric hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis 2021;102:233–8.
22 Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxia is baffling to physicians. Am J Respir Crit Care Med 2020;202:356–60.
23 Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82.
24 Iacca G, Grassi G, Borghi C, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension. Hypertension 2020;76:366–72.
25 Tutty Kuswardhani RA, Henrina J, Pranata R, et al. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:2103–9.
26 Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997;107:1469–75.
27 Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001;37:337–42.
28 Tessier A, Finch L, Daskalopoulou SS, et al. Validation of the Charlson comorbidity index for predicting functional outcome of stroke. Arch Phys Med Rehabil 2008;89:1276–83.
29 Christensen S, Johansen MB, Christiansen CF, et al. Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011;3:203–11.
30 Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213–7.
31 Ministère des Solidarités et de la Santé. 728 000 résidents en établissements d’hébergement pour personnes âgées en 2015 [online]. Available: https://drees.solidarites-sante.gouv.fr/etudes-et-resultats/article/728-000-residents-en-etablissements-d-hebergement-pour-personnes-agees-en-2015
32 Bulletin de l’Académie Nationale de Médecine. The resumption of surgical activities: a health emergency and a contribution to the economic recovery, 2020.
33 Chan-Chee C, Léon C, Lasbeur L, et al. The mental health of the French facing the COVID-19 crisis: prevalence, evolution and determinants of anxiety disorders during the first two weeks of lockdown (coviprev study, March 23–25 and March 30 – April 1st, 2020) (Santé Publique France).
34 Menzies RE, Menzies RG. Death anxiety in the time of COVID-19: theoretical explanations and clinical implications. Cogn Behav Therap 2020;13:e19.
35 Bersano A, Kraemer M, Touzé E, et al. Stroke care during the COVID-19 pandemic: experience from three large European countries. Eur J Neurol 2020;27:1794–800.
36 Christensen DM, Strange JE, Gislason G, et al. Charlson comorbidity index score and risk of severe outcome and death in Danish COVID-19 patients. J Gen Intern Med 2020;35:2801–3.
37 Peretti-Watel P, Alleaume C, Léger D, et al. Anxiety, depression and sleep problems: a second wave of COVID-19. Gen Psychiatr 2020;33:e100299.